Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05262621
Other study ID # TheNethersole
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 8, 2022
Est. completion date August 10, 2022

Study information

Verified date April 2023
Source The Nethersole School of Nursing
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study design A 2-arm, assessor-blinded randomised controlled trial will be conducted. The design will follow the Standard Protocol Items Recommendations for Interventional Trials (SPIRIT)


Description:

Aim: To assess the effect of MCP on anxiety, depression and QoL of BGC patients receiving chemotherapy. Objectives - To assess the effect of MCP on the anxiety of BGC patients receiving chemotherapy. - To assess the effect of MCP on depression of BGC patients receiving chemotherapy. - To assess the effect of MCP on QoL and patients' satisfaction of BGC patients receiving chemotherapy. - To determine whether stress level, coping and coping styles mediate the intervention effect on anxiety, depression and QoL. Hypothesis - The participants receiving MCP will have a significantly lower level of anxiety compared to the control group. - The participants receiving MCP will have a significantly lower level of depression compared to the control group. - The participants receiving MCP will have significantly higher QoL scores and levels of satisfaction with care service compared to the control group. - Stress level, coping will mediate the intervention on target outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date August 10, 2022
Est. primary completion date August 2, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Women with breast or gynaecological cancer are 18 years of age or older, and are independent legally to sign the consent form. - Living with family and having an adult family member agree to participate in the meeting part of the program. - Had been informed the cancer diagnosis - Have Karnofsky score (Mor et al., 1984) = 80 ( to be able to self-practice MCP) - Can communicate, read and write in Vietnamese - Have a device such as a smartphone, MP3 to keep the audio file (to self-practice MCP at home) - Consent to join the study Exclusion Criteria: - The patients cannot understand the study procedures - Have mental health illness, deafness, blindness - Have not been aware of their cancer or the purpose of chemotherapy - Be participating in other studies related to psychological issues - Be receiving anxiety or depression treatment. - Be participating in relaxation therapy such as yoga, meditation, mindfulness, PMR... - Have a potential treatment (eg. surgery) or personal plans that will prevent them from practising daily during the 6 weeks of the intervention.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
progressive muscle relaxation
Practice muscle relaxation for 20 minutes once/a day
Listening to relaxing music once/day
Right after practising progressive muscle relaxation, the participants will listen to relaxing music for 20 minutes

Locations

Country Name City State
Vietnam Vietnam National Cancer Institute, Hanoi Oncology Hospital Hanoi

Sponsors (1)

Lead Sponsor Collaborator
The Nethersole School of Nursing

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline anxiety at 3 weeks and 6 weeks it will be measured using the short form of the Depression Anxiety Stress Scale (DASS-21). It includes 7 items for anxiety (DASS21-A). A 4-point Likert-type scale ranging from 0 to 3 was designed for each item, and the scores will need to be multiplied by 2 to calculate the final score. Thus, the anxiety score can range from 0 to 42. The higher the score is the more severe anxiety. The score of 0-7 is normal, 8-9 mild, 10-14 moderate, 15-19 severe, +20 extremely severe. ebaseline, T1 after 3 weeks, T2 after 6 weeks
Primary Change from baseline depression at 3 weeks and 6 weeks it will be measured using the short form of the Depression Anxiety Stress Scale (DASS-21). It includes 7 items for depression (DASS21-D). A 4-point Likert-type scale ranging from 0 to 3 was designed on each item, and the scores will need to be multiplied by 2 to calculate the final score. Thus, the depression score can range from 0 to 42. The higher the score is the more severe depression. The score of 0-9 is normal, 10-13 mild, 14-20 moderate, 21-27 severe, +28 extremely severe. baseline, T1 after 3 weeks, T2 after 6 weeks
Secondary Change from baseline stress at 3 weeks and 6 weeks it will be measured using the short form of the Depression Anxiety Stress Scale (DASS-21). It includes 7 items for stress (DASS21-S). A 4-point Likert-type scale ranging from 0 to 3 was designed for each item, and the scores will need to be multiplied by 2 to calculate the final score. Thus, the stress score can range from 0 to 42. The higher the score is the more severe stress. The score of 0-14 is normal, 15-18 mild, 19-25 moderate, 26-33 severe, +34 extremely severe. baseline, T1 after 3 weeks, T2 after 6 weeks
Secondary Change from baseline coping styles at 3 weeks and 6 weeks Coping will be measured using Brief COPE. The Brief-COPE is a 28 item self-report questionnaire designed to measure effective and ineffective ways to cope with a stressful life event.The scale can determine someone's primary coping styles with scores on the following three subscale:
Problem-Focussed Coping, Emotion-Focussed Coping, Avoidant Coping.A 4-point Likert-type scale ranging from 1 to 4 was designed on each item.
baseline, T1 after 3 weeks, T2 after 6 weeks
Secondary Change from baseline quality of life at 3 weeks and 6 weeks coping will be measured using FACT-G.It evaluates in functional scales on Social/family well-being (SWB); Emotional well-being (EWB) and Functional well-being (FWB). Each item is scored in one of five categories of 0-4, with 'Not at all', 'A little bit', 'some what', 'Quite a bit' 'Very much'. The higher the score is the better quality of life." The possible range of scores is from 0 to 112. baseline, T1 after 3 weeks, T2 after 6 weeks
Secondary Change from baseline satisfaction of nursing care at 3 weeks satisfaction of nursing care will be measured using numerical rating scale.(0-10) from 0 = completely dissatisfied with the care to 10 = completely satisfied with the care. baseline, T1 after 3 weeks,
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients